|
| Figure 2: Mean (SD) plasma concentration-time profiles for canagliflozin following administration of two canagliflozin/metformin FDC IR tablets (A) 150 mg/500 mg (B) 150 mg/850 mg and (C) 150 mg/1,000 mg and coadministration of canagliflozin + metformin IR individual tablets (A) 300 mg + 2x 500 mg (B) 300 mg + 2x 850 mg, and (C) 300 mg + 2x 1,000 mg (Studies 4-6). |
